What's in Store for West Pharmaceutical (WST) in Q2 Earnings?

Q2 Estimates Factors to Note However, destocking, as well as the timing of new high-value product (HVP) device capacity and customer-led HVP upgrade, is likely to have led to a decline in second-quarter sales. Moreover, a weak pharma market and declining sales related to COVID-19 vaccines are expected to have offset growth in other products. The company is also expected to have witnessed a gross margin expansion in the aforementioned segment. This was likely due to a favorable mix of products sold (stemming ...